RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
 Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Research Article
Latest Research Channel

subscribe to Latest Research newsletter
Latest Research

   EMAIL   |   PRINT
For heart failure patients, certain findings on ECG predicts risk of rehospitalization and death

Jun 10, 2008 - 4:00:00 AM
In this analysis, a prolonged QRS duration was present in 45 percent of patients admitted with heart failure and reduced LVEF, did not appear to significantly change during hospitalization, and was independently associated with high postdischarge mortality and readmission rate. This high morbidity and mortality was observed even though patients were well-treated with standard medical therapy that included beta-blockers and angiotensin-converting enzyme [ACE] inhibitors or angiotensin II receptor blockers [ARBs], the authors write.

 
[RxPG] Among patients hospitalized with heart failure, having a longer than normal QRS duration (a measurement of the electrical conducting time of the heart on an electrocardiogram (ECG)] appears to predict a high risk of death or rehospitalization within a few months after discharge, according to a study in the June 11 issue of JAMA.

An ECG is routinely obtained on all patients admitted with heart failure. Hospitalization for heart failure is a major public health problem in the developed world, with the United States and Europe each reporting more than 1 million heart failure hospitalizations per year. The frequency and the predictive value of a prolonged QRS duration during an admission for heart failure has not been well studied. Establishing the prognostic value of a prolonged QRS duration during hospitalization for heart failure may aid in tailoring therapy to improve postdischarge morbidity and mortality, according to background information.

Mihai Gheorghiade, M.D., and Norman C. Wang, M.D., of the Northwestern University Feinberg School of Medicine, Chicago, and investigators with the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) trial, investigated the relationship of QRS duration and changes during the course of hospitalization to outcomes such as death and hospitalization for heart failure. The study included 4,133 patients hospitalized for heart failure and having a left ventricular ejection fraction (LVEF; a measure of how well the left ventricle of the heart pumps with each contraction) of 40 percent or less. After excluding 1,029 patients with a pacemaker, implantable cardioverter-defibrillator, or both at enrollment and 142 patients without a reported baseline QRS duration, 2,962 patients were included in this analysis: 1,641 had a normal QRS duration (less than 120 ms) and 1,321 had a prolonged QRS duration (120 ms or greater). Median (midpoint) follow-up time was 9.9 months.

There were 678 total deaths (307 of 1,641 patients [18.7 percent] with a normal baseline QRS duration and 371 of 1,321 [28.1 percent] with a prolonged baseline QRS duration). The most common cause of death was heart failure followed by sudden cardiac death. The composite of cardiovascular death or hospitalization for heart failure was more frequent in patients with a prolonged baseline QRS duration at 3 months after enrollment (21.1 percent vs. 14.6 percent) and at the end of the follow-up period of 9.9 months (41.6 percent vs. 32.4 percent). After adjusting for multiple variables, compared with normal baseline QRS duration, prolonged QRS duration was associated with a 24 percent increased risk of death and a 28 percent increased risk for the composite of cardiovascular death or hospitalization for heart failure.

In this analysis, a prolonged QRS duration was present in 45 percent of patients admitted with heart failure and reduced LVEF, did not appear to significantly change during hospitalization, and was independently associated with high postdischarge mortality and readmission rate. This high morbidity and mortality was observed even though patients were well-treated with standard medical therapy that included beta-blockers and angiotensin-converting enzyme [ACE] inhibitors or angiotensin II receptor blockers [ARBs], the authors write.

Measurement of the QRS duration on an ECG has significant advantages as a tool in the clinical setting. It is relatively inexpensive, simple to perform, and yields an instant result. The measurement is objective and does not require specialized training to interpret. In addition, the QRS duration is stable in the majority of patients during the course of their hospitalization. Perhaps most important, a prolonged QRS duration becomes a potential target for intervention [with existing therapy], which may improve postdischarge mortality and morbidity.




Advertise in this space for $10 per month. Contact us today.


Related Latest Research News


Subscribe to Latest Research Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)